JP2017538671A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538671A5 JP2017538671A5 JP2017521577A JP2017521577A JP2017538671A5 JP 2017538671 A5 JP2017538671 A5 JP 2017538671A5 JP 2017521577 A JP2017521577 A JP 2017521577A JP 2017521577 A JP2017521577 A JP 2017521577A JP 2017538671 A5 JP2017538671 A5 JP 2017538671A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- sdab
- pharmaceutical composition
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019149269A JP6928773B2 (ja) | 2014-10-23 | 2019-08-16 | 細胞内抗原に対して指向された単一ドメイン抗体 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067908P | 2014-10-23 | 2014-10-23 | |
| US62/067,908 | 2014-10-23 | ||
| US201562148656P | 2015-04-16 | 2015-04-16 | |
| US62/148,656 | 2015-04-16 | ||
| US201562188353P | 2015-07-02 | 2015-07-02 | |
| US62/188,353 | 2015-07-02 | ||
| US201562210795P | 2015-08-27 | 2015-08-27 | |
| US62/210,795 | 2015-08-27 | ||
| PCT/US2015/057223 WO2016065323A2 (en) | 2014-10-23 | 2015-10-23 | Single domain antibodies directed against intracellular antigens |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019062231A Division JP6670963B2 (ja) | 2014-10-23 | 2019-03-28 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2019149269A Division JP6928773B2 (ja) | 2014-10-23 | 2019-08-16 | 細胞内抗原に対して指向された単一ドメイン抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017538671A JP2017538671A (ja) | 2017-12-28 |
| JP2017538671A5 true JP2017538671A5 (enExample) | 2018-11-29 |
Family
ID=55761757
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017521577A Pending JP2017538671A (ja) | 2014-10-23 | 2015-10-23 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2019062231A Active JP6670963B2 (ja) | 2014-10-23 | 2019-03-28 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2019149269A Active JP6928773B2 (ja) | 2014-10-23 | 2019-08-16 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2021105631A Active JP6986180B2 (ja) | 2014-10-23 | 2021-06-25 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2021192139A Active JP7195400B2 (ja) | 2014-10-23 | 2021-11-26 | 細胞内抗原に対して指向された単一ドメイン抗体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019062231A Active JP6670963B2 (ja) | 2014-10-23 | 2019-03-28 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2019149269A Active JP6928773B2 (ja) | 2014-10-23 | 2019-08-16 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2021105631A Active JP6986180B2 (ja) | 2014-10-23 | 2021-06-25 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2021192139A Active JP7195400B2 (ja) | 2014-10-23 | 2021-11-26 | 細胞内抗原に対して指向された単一ドメイン抗体 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20160115247A1 (enExample) |
| EP (3) | EP3209685B1 (enExample) |
| JP (5) | JP2017538671A (enExample) |
| KR (4) | KR102207381B1 (enExample) |
| CN (2) | CN111848793B (enExample) |
| AU (4) | AU2015335600B2 (enExample) |
| BR (4) | BR122020006914B8 (enExample) |
| CA (3) | CA2962275C (enExample) |
| CY (2) | CY1122035T1 (enExample) |
| DK (2) | DK3209685T3 (enExample) |
| ES (2) | ES2731876T3 (enExample) |
| HR (2) | HRP20191056T1 (enExample) |
| HU (2) | HUE047601T2 (enExample) |
| IL (2) | IL289769B2 (enExample) |
| LT (2) | LT3590962T (enExample) |
| MX (2) | MX379450B (enExample) |
| PL (2) | PL3590962T3 (enExample) |
| PT (2) | PT3590962T (enExample) |
| RS (2) | RS62694B1 (enExample) |
| RU (1) | RU2017116710A (enExample) |
| SI (2) | SI3209685T1 (enExample) |
| SM (2) | SMT201900413T1 (enExample) |
| TW (1) | TWI664289B (enExample) |
| WO (1) | WO2016065323A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180072815A1 (en) | 2014-10-23 | 2018-03-15 | Singh Biotechnology, Llc | Single Domain Antibodies Directed Against Intracellular Antigens |
| US20170267784A1 (en) * | 2014-10-23 | 2017-09-21 | Singh Molecular Medicine, Llc | Single domain antibodies directed against intracellular antigens |
| US20160115247A1 (en) | 2014-10-23 | 2016-04-28 | Singh Biotechnology, Llc | Single domain antibodies directed against intracellular antigens |
| CA3255406A1 (en) | 2015-03-31 | 2025-07-03 | Sorriso Pharmaceuticals, Inc. | Tnf-alpha binding polypeptides |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| SG11201706840WA (en) | 2015-03-31 | 2017-09-28 | Vhsquared Ltd | Peptide construct having a protease-cleavable linker |
| PE20181295A1 (es) | 2015-09-01 | 2018-08-07 | First Wave Bio Inc | Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala |
| TWI746473B (zh) | 2015-11-02 | 2021-11-21 | 美商辛分子醫藥有限公司 | 針對細胞內抗原之單域抗體 |
| CN108603037B (zh) * | 2015-12-10 | 2020-11-17 | 希望之城 | 细胞穿透花青偶联抗体 |
| EP3519438A1 (en) | 2016-09-30 | 2019-08-07 | VHsquared Limited | Compositions |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| KR20190076354A (ko) * | 2017-12-22 | 2019-07-02 | 주식회사 로피바이오 | 세포 내 침투능을 갖는 항 stat3 이중특이 항체를 포함하는, 염증성 질환 치료용 약학적 조성물 |
| EP3730150A4 (en) | 2017-12-22 | 2021-10-06 | Rophibio, Inc. | ANTI-STAT3 BISPECIFIC ANTIBODY WITH CELL-PENETRATING ABILITY AND THIS PHARMACEUTICAL COMPOSITION |
| US20210123061A1 (en) * | 2018-05-04 | 2021-04-29 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treating inflammatory disease or disorder |
| CN113518783A (zh) | 2018-07-20 | 2021-10-19 | 动量制药公司 | FcRn抗体组合物 |
| KR102101561B1 (ko) * | 2018-07-25 | 2020-04-20 | 가톨릭대학교 산학협력단 | 신생혈관 표적용 조영제 조성물 및 이의 제조방법 |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| US12559552B2 (en) | 2019-06-21 | 2026-02-24 | Sorriso Pharmaceuticals, Inc. | IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides |
| CA3144567A1 (en) | 2019-06-21 | 2020-12-24 | Scott Crowe | Polypeptides |
| KR20220063148A (ko) | 2019-06-21 | 2022-05-17 | 소리소 파마슈티컬스 인크. | 조성물 |
| CN110357965A (zh) * | 2019-06-24 | 2019-10-22 | 浙江大学 | 一种突变型kras特异性抗体及其制备方法 |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| IL295810B2 (en) | 2020-03-11 | 2026-01-01 | Univ Pennsylvania | Methods and compositions for gene delivery using a modified viral particle |
| US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| CN115215939B (zh) * | 2021-04-14 | 2025-09-23 | 中山大学 | 一种融合蛋白及其制备方法与应用 |
| MX2024000309A (es) * | 2021-07-07 | 2024-04-09 | Singh Biotechnology Llc | Supresión de la uveítis mediante anticuerpos de dominio único. |
| EP4392459A4 (en) * | 2021-08-27 | 2026-03-18 | Singh Biotechnology Llc | SINGLE-DOMAIN THERAPEUTIC ANTIBODY |
| IL313473A (en) | 2021-12-15 | 2024-08-01 | Interius Biotherapeutics Inc | Pseudotyped viral particles, compositions comprising the same, and uses thereof |
| WO2024003873A1 (en) * | 2022-06-30 | 2024-01-04 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Single variable domain antibodies against tumor necrosis factor-alpha |
| KR20250057777A (ko) | 2022-07-25 | 2025-04-29 | 인테리우스 바이오테라퓨틱스, 인코포레이티드 | 돌연변이된 폴리펩티드, 이를 포함하는 조성물, 및 그 용도(mutated polypeptides, compositions comprising the same, and uses thereof) |
| WO2024163894A1 (en) | 2023-02-04 | 2024-08-08 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating hemolytic disease of the fetus and newborn |
| WO2025004683A1 (ja) * | 2023-06-30 | 2025-01-02 | 国立大学法人大阪大学 | がん検査方法及びがん治療剤 |
| AR133412A1 (es) | 2023-07-30 | 2025-09-24 | Janssen Biotech Inc | Moléculas que se unen a la calreticulina mutante y usos de estas |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025099576A1 (en) | 2023-11-06 | 2025-05-15 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating rheumatoid arthritis |
| TW202540161A (zh) | 2023-11-21 | 2025-10-16 | 美商健生生物科技公司 | 治療骨髓增生性腫瘤之方法 |
| WO2025163617A1 (en) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
| WO2025257810A1 (en) * | 2024-06-14 | 2025-12-18 | Singh Biotechnology, Llc | Suppression of neurodegenerative diseases by single domain antibody |
| WO2026083290A1 (en) | 2024-10-16 | 2026-04-23 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| AU687010B2 (en) * | 1992-07-17 | 1998-02-19 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
| FR2706486B1 (fr) * | 1993-06-16 | 1995-09-01 | Rhone Poulenc Rorer Sa | Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques. |
| EP1204674A4 (en) | 1999-07-27 | 2005-06-01 | Abgenix Inc | METHODS AND COMPOUNDS FOR PREVENTING POLYPEPTIDE COLLECTIONS ASSOCIATED WITH NEUROLOGICAL DISORDERS |
| US6277974B1 (en) * | 1999-12-14 | 2001-08-21 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
| DE10019157A1 (de) | 2000-04-18 | 2001-11-15 | Stefan Duebel | Verfahren zum Einbringen von Liganden in lebende Zellen |
| CA2441903C (en) | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| US20040052762A1 (en) | 2001-09-10 | 2004-03-18 | Hua Yu | Stat3 agonists and antagonists and therapeutic uses thereof |
| AU2002246737B2 (en) * | 2000-12-29 | 2007-03-01 | Savient Pharmaceuticals, Inc. | Specific human antibodies for selective cancer therapy |
| WO2003077945A1 (en) * | 2002-03-14 | 2003-09-25 | Medical Research Council | Intracellular antibodies |
| GB0226727D0 (en) * | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
| ZA200503075B (en) * | 2002-11-07 | 2006-09-27 | Immunogen Inc | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
| US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| WO2004041863A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
| EP1558645B1 (en) * | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
| EP1900753B1 (en) | 2002-11-08 | 2017-08-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
| GB0226729D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intracellular antibodies |
| US7638122B2 (en) | 2003-03-07 | 2009-12-29 | University Of South Florida | Stat3 antagonists and their use as vaccines against cancer |
| US20050226863A1 (en) | 2003-11-20 | 2005-10-13 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| DE102005023617A1 (de) | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| EP2077863A4 (en) | 2006-10-31 | 2010-10-06 | Domantis Ltd | intrabodies |
| CA2588106A1 (en) * | 2007-05-18 | 2008-11-18 | Nrc - Institute For Biological Sciences | Single-domain antibodies and heavy chain antibody against egfr and uses thereof |
| EP2008666A1 (en) | 2007-06-29 | 2008-12-31 | Institut Pasteur | Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications |
| US20110195509A1 (en) * | 2007-09-06 | 2011-08-11 | Drew Pardoll | Treatment of th17-mediated autoimmune disease via inhibition of stat 3 |
| BRPI0910198A2 (pt) * | 2008-06-30 | 2016-01-12 | Silenseed Ltd | composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo. |
| EP2143735A1 (en) * | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
| WO2010033913A1 (en) * | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| US20130177979A1 (en) | 2010-06-22 | 2013-07-11 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for cell permeable stat3 inhibitor |
| US9879093B2 (en) * | 2011-12-20 | 2018-01-30 | Adaerata, Limited Partnershp | Single domain antibodies as inhibitors of PCSK9 |
| HRP20190303T1 (hr) * | 2012-10-31 | 2019-05-17 | Ionis Pharmaceuticals, Inc. | Liječenje raka |
| AU2014227824B2 (en) * | 2013-03-15 | 2018-09-27 | Dana-Farber Cancer Institute, Inc. | Stabilized SOS1 peptides |
| JP6570512B2 (ja) * | 2013-03-22 | 2019-09-04 | ユニバーシティ・オブ・ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ | 新規なＳｔａｔ３阻害剤 |
| CN103368197B (zh) | 2013-07-15 | 2015-11-25 | 国家电网公司 | 模块化多电平换流器的阀基控制设备和方法 |
| CN105658230B (zh) | 2013-08-29 | 2020-04-21 | 希望之城 | 细胞穿透缀合物及其使用方法 |
| EP2873680A1 (en) | 2013-11-13 | 2015-05-20 | F.Hoffmann-La Roche Ag | Oligopeptide and methods for producing conjugates thereof |
| EP2899208A1 (en) | 2014-01-28 | 2015-07-29 | F.Hoffmann-La Roche Ag | Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof |
| US20160115247A1 (en) | 2014-10-23 | 2016-04-28 | Singh Biotechnology, Llc | Single domain antibodies directed against intracellular antigens |
-
2015
- 2015-10-23 US US14/922,081 patent/US20160115247A1/en not_active Abandoned
- 2015-10-23 WO PCT/US2015/057223 patent/WO2016065323A2/en not_active Ceased
- 2015-10-23 CA CA2962275A patent/CA2962275C/en active Active
- 2015-10-23 RU RU2017116710A patent/RU2017116710A/ru not_active Application Discontinuation
- 2015-10-23 CN CN202010738353.7A patent/CN111848793B/zh not_active Expired - Fee Related
- 2015-10-23 DK DK15853465.1T patent/DK3209685T3/da active
- 2015-10-23 PL PL19165430T patent/PL3590962T3/pl unknown
- 2015-10-23 BR BR122020006914A patent/BR122020006914B8/pt active IP Right Grant
- 2015-10-23 BR BR122020006918A patent/BR122020006918B8/pt active IP Right Grant
- 2015-10-23 HR HRP20191056TT patent/HRP20191056T1/hr unknown
- 2015-10-23 SM SM20190413T patent/SMT201900413T1/it unknown
- 2015-10-23 SI SI201530789T patent/SI3209685T1/sl unknown
- 2015-10-23 US US14/922,098 patent/US9663570B2/en active Active
- 2015-10-23 SM SM20210695T patent/SMT202100695T1/it unknown
- 2015-10-23 KR KR1020197026708A patent/KR102207381B1/ko active Active
- 2015-10-23 LT LTEP19165430.0T patent/LT3590962T/lt unknown
- 2015-10-23 TW TW104134979A patent/TWI664289B/zh active
- 2015-10-23 SI SI201531763T patent/SI3590962T1/sl unknown
- 2015-10-23 KR KR1020187004337A patent/KR102023289B1/ko active Active
- 2015-10-23 PT PT191654300T patent/PT3590962T/pt unknown
- 2015-10-23 DK DK19165430.0T patent/DK3590962T3/da active
- 2015-10-23 CA CA3052777A patent/CA3052777C/en active Active
- 2015-10-23 US US14/922,093 patent/US9695234B2/en active Active
- 2015-10-23 AU AU2015335600A patent/AU2015335600B2/en active Active
- 2015-10-23 BR BR122020006907A patent/BR122020006907B8/pt active IP Right Grant
- 2015-10-23 LT LTEP15853465.1T patent/LT3209685T/lt unknown
- 2015-10-23 EP EP15853465.1A patent/EP3209685B1/en active Active
- 2015-10-23 RS RS20211519A patent/RS62694B1/sr unknown
- 2015-10-23 HU HUE15853465A patent/HUE047601T2/hu unknown
- 2015-10-23 BR BR112017008165A patent/BR112017008165B8/pt active IP Right Grant
- 2015-10-23 US US14/922,100 patent/US9546211B2/en active Active
- 2015-10-23 KR KR1020177006630A patent/KR101831123B1/ko active Active
- 2015-10-23 PL PL15853465T patent/PL3209685T3/pl unknown
- 2015-10-23 ES ES15853465T patent/ES2731876T3/es active Active
- 2015-10-23 IL IL289769A patent/IL289769B2/en unknown
- 2015-10-23 CN CN201580056968.9A patent/CN106852148B/zh active Active
- 2015-10-23 HR HRP20211889TT patent/HRP20211889T1/hr unknown
- 2015-10-23 JP JP2017521577A patent/JP2017538671A/ja active Pending
- 2015-10-23 EP EP19165430.0A patent/EP3590962B1/en active Active
- 2015-10-23 CA CA3114318A patent/CA3114318A1/en active Pending
- 2015-10-23 RS RS20190750A patent/RS59063B1/sr unknown
- 2015-10-23 EP EP21192390.9A patent/EP4006052A1/en active Pending
- 2015-10-23 HU HUE19165430A patent/HUE057605T2/hu unknown
- 2015-10-23 PT PT15853465T patent/PT3209685T/pt unknown
- 2015-10-23 MX MX2017003268A patent/MX379450B/es unknown
- 2015-10-23 ES ES19165430T patent/ES2900253T3/es active Active
- 2015-10-23 KR KR1020197026711A patent/KR102207382B1/ko active Active
-
2017
- 2017-03-06 IL IL250961A patent/IL250961B/en unknown
- 2017-03-10 MX MX2021001098A patent/MX2021001098A/es unknown
-
2019
- 2019-03-28 JP JP2019062231A patent/JP6670963B2/ja active Active
- 2019-06-28 AU AU2019204614A patent/AU2019204614B2/en not_active Ceased
- 2019-07-03 CY CY20191100706T patent/CY1122035T1/el unknown
- 2019-08-16 JP JP2019149269A patent/JP6928773B2/ja active Active
-
2021
- 2021-01-22 AU AU2021200416A patent/AU2021200416B2/en not_active Ceased
- 2021-06-25 JP JP2021105631A patent/JP6986180B2/ja active Active
- 2021-11-26 JP JP2021192139A patent/JP7195400B2/ja active Active
- 2021-12-09 CY CY20211101082T patent/CY1124867T1/el unknown
-
2022
- 2022-06-15 AU AU2022204167A patent/AU2022204167A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538671A5 (enExample) | ||
| RU2017116710A (ru) | Однодоменные антитела, направленные против внутриклеточных антигенов | |
| Hong et al. | Hepatic stellate cells express functional CXCR4: Role in stromal cell–derived factor‐1α–mediated stellate cell activation | |
| US20210024893A1 (en) | Medical uses of exosomes | |
| Li et al. | Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress | |
| Suzukawa et al. | Leptin enhances ICAM-1 expression, induces migration and cytokine synthesis, and prolongs survival of human airway epithelial cells | |
| Deng et al. | Targeting transmembrane BAX inhibitor motif containing 1 alleviates pathological cardiac hypertrophy | |
| JP2016530323A5 (enExample) | ||
| JP2015506944A5 (enExample) | ||
| EA201100641A1 (ru) | Антитела к il-6 и их применение | |
| JP2019504107A5 (enExample) | ||
| EA201991704A3 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| Guan et al. | Ginsenoside Rg3 ameliorates acute exacerbation of COPD by suppressing neutrophil migration | |
| EP3120142A2 (en) | Use of compounds inhibiting apelin / apj / gp130 signaling for treating cancer | |
| JP6918005B2 (ja) | 細胞内抗原に対して向けられた単一ドメイン抗体 | |
| Nkongolo et al. | The retinoic acid receptor (RAR) α-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA | |
| RU2013104039A (ru) | Способ идентификации пациента с повышенной вероятностью ответа на противораковую терапию | |
| Li et al. | Cellular communication network factor 1 promotes retinal leakage in diabetic retinopathy via inducing neutrophil stasis and neutrophil extracellular traps extrusion | |
| Ji et al. | RETRACTED ARTICLE: TAZ inhibition promotes IL-2-induced apoptosis of hepatocellular carcinoma cells by activating the JNK/F-actin/mitochondrial fission pathway | |
| Mahmood et al. | Azilsartan as “Add‐On” Treatment with Methotrexate Improves the Disease Activity of Rheumatoid Arthritis | |
| Zhang et al. | Human hemokinin-1 promotes migration of melanoma cells and increases MMP-2 and MT1-MMP expression by activating tumor cell NK1 receptors | |
| Zeng et al. | Glial cell line-derived neurotrophic factor ameliorates dextran sulfate sodium-induced colitis in mice via a macrophage-mediated pathway | |
| Xu et al. | Microglial NLRC5 drives lysosomal dysfunction to disrupt autophagic flux and promote post-stroke neuroinflammation | |
| JP2015517500A5 (enExample) | ||
| JP2012521549A5 (enExample) |